Allogene Therapeutics (ALLO) 13 May 242024 Q1 Earnings call transcript

Hello, and welcome to the Allogene Therapeutics First Quarter 2024 Conference Call. [Operator Instructions]. Please be aware that today's conference is being recorded. We ask that you limit yourself to 1 question only.

I would now like to turn the conference over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer.

begin. may You

results and both call. operator, a all have and and who release XXXX. quarter Thank press on This the welcome our market this release financial update business After provides webcast issued the closed joined first that of are you, today's a to for available today, press Allogene website.

this will questions call We ask we limit your to Following do per to session. will an our our possible. you get many to Q&A keep prepared hour and to host a remarks, questions as one we person best to as as

Parker, Joining Zachary Financial Chang, Roberts, me President Officer. and David President Dr. Vice Jeff Officer; Research of Executive Medical Chief today Executive Chief Dr. Development and are and Chief and Officer;

making regulatory statements. and will risks our cell and future based may timing latest During expanded These statements are other be success disclosure product These A candidates among presentations, we ongoing development of manufacturing efficacy regarding the our today's data filings, call, certain trials, forward-looking safety the things. and XXXX to and capabilities, of expectations research of our efforts, guidance clinical in and documents. are be financial statements change. description potential and assumptions planned found subject current forward-looking that press information, on release development and can SEC stem include

disclaims any update not undue forward-looking to place reliance and cautioned obligation to Allogene are statements. these You on these statements,

I'll the now to turn over call David.

those welcome and to Christine, on the you, today. call Thank

opportunity focus rights $X our [ approximately on Union designed allogeneic increased. frontline from leadership programs In billion. ] In B-cell million every to later we address market you differentiated to data, into market the unmet meant than so, how from our dramatically grew our moving and time Servier. continued more to $XXX meant It to development include needs. January, something consolidate pivot and have lymphoma from significant. the competitive to our front. with all opportunity excited future the line strengthen U.K. was to In U.S. on speak to territory of today That the are change large that we announced to importantly We alone, the extend doing position European discuss

to that We executed are and more call. excited agreement will on have on Jeff that provide vision details this

in Our X outlined progress core January. we team in making is programs great

stem in large is We a proud are the XXXX, cell, is to and very designed the pivotal trial transformative care potential curative to out of of leading first-line patients standard with expected change the XXXX. stem with This ALPHAX to for cell B-cell potential has submission regimen BLA of potential our read of in as trial lymphoma. which to part

in is rare oncology. The as want being to emphasize I point that very last something

Our new stem leukemia ] a could dual infusion. declared is needs immune patients lymphocytic a what goal a for technology CDXX with of editing chronic for refractory achieve CAR critical standard with cell the or also our autoimmune We Differentiation core program can across programs. space move into a relapse T set disease. in CRISPR-based [ and our our is gene system of integration, setting single autoimmune to which CAR, next-generation the CDXX with unique the designed incorporates meet ALLO-XXX, Dagger CLL. site-specific

autoimmune and which ALLO-XXX path believe in we indications. Our lymphodepletion, commercial data reducing eliminating for potential create technology provides opportunities a or development may to more

trial with Regenerative Institute for ALLO-XXX and potential CAR last made demonstrate could tumor. to carcinoma. solid therapeutic ALLO-XXX the million in advanced month be validates in Medicine the remarkable believe our cell our California a potential for $XX first the patients has the awarded grant, Our of enrolls program We unique renal T TRAVERSE

of the I completion funds [ the Phase trial. grant ] This

the potential to of recognition the for patients. make ] difference for a from [ for We grateful ALLO-XXX are the reviewers service

We the our third are commitment who excited of quarter into I XXXX. participated cash investors to am mission. by to very demonstrated have and pleased caliber to their strengthened runway in extend our this financing

members in and In this being it the management our across programs. of ALPHAX on executive focused Executive X our appreciate by Chair, our participating pivotal Jeff, Later to further Arie Board have Belldegrun, our core are all [ I all our many Zach Understandably, commitment our programs. Allogene points in related the review ] multitude to and to CFO, offering. the milestones client demonstrated in across development but trial, milestones addition, is inflection of call, essential will investors

core our all focus to to positioned ] benefit these our patients. [ believe continue we resources advancing to and treatment on will programs We change are well landscape

the over to today. call our Jeff would like to announcement review to turn I

Thank David. you,

the expect the conversations, those made renewed interim mutual start analysis and and me our the institutional is we efficacy of just our builds of top-tier financing that the critical. we and the Let first When We million to release advancing with we on our strategic issued have press investors interest our runway [ funds. to pursue half extends trial. announcing from XXXX, decision strong our $XXX second know enrollment into runway cash earlier year, pivot this had reserves which during a cash Based ]. that we announced to ALPHAX time complete we

funds, belief part to and and Many execute we look indicative depth investor management validating our and In goals. addition, mutual Board of the investors reshapes their Directors this select [ of interest care largest including of our CAR as allogeneic and on team in the Allogene specialists our we base. of investors strategy in who is are ] forward T financing this raise, the leading of of health of members institutional our importantly X

our to our belief with in is our Another example underscores Servier. amendment completed that agreement just programs our

ago was X formed, the factors. they to for You years rights by timing under agreement. when few now may recall became cell when rights versus a we available, had obtain The the for was important only Allogene stem that Servier first U.S. us these driven

opportunity and LBCL and strategic CLL, with increased future consolidation frontline the the market now First, to ability two, establish partnerships. dramatically

Let market me the start with opportunity.

was in third approximately and first-line At a pivot million our cell January United than in consolidation After trial announced into time, refractory our States. dramatically $X LBCL opportunity CLL, new for billion lead $XXX of LBCL. to before indication. estimated in Our opportunity program this in we increased market relapsed that market for announcement line sema our the that in more

and our than to future for to the significantly revenue at no additional We and also the just demonstrate cell we to more rights China option U.K. cost that potential $X.X add the member Japan have by turn, the when resources expands cell increase negotiated to EU [ our sema than region. increasing ] We further states XX%. market with opportunity more sema now in opportunity adding In by billion. Servier advance the can were

This partnerships. brings me future two, to strategic point number

might partner opportunity for have how the control used months product more malignancies. in this validated centers, heme community T commercial X markets, a We in over to the potential where is agreement, growing transform only you clinically making surmise and excitement potential Given this key cell a as partnership. only With the in And program XX next cancer risked. allogeneic sema market rights the attractive. interest excitement will and in consolidated we grow CAR positioned are CAR-Ts CDXX to

cell. given favorable that $XX $XX opportunity milestones overall for by obligation expanded cost sell minimal Importantly, to by million. agreed financial we increase the milestones on our geography. Allogene compared for The market is regulatory increases and to our sema are did a terms quite We've the million commercial at

have remains a effectively in modestly in increases burn the and XXs U.K. the but EU XX% royalty flat low royalty mid-teens to Our and same U.S. the we territory in the the

and royalty XX% Our would we pursue China. if be rights in also our Japan

the quarter just our announced and the now update financial turn Let financing. our impact first for me to of

cash forma cash announced XXXX will end as $XXX the Our our cash, million. cash to for we balance financing in investments. million of equivalents today, $XXX.X balance the Pro increase approximately and of was QX

Our into half cash XXXX. second extends now runway of the

development compensation. which QX in associated includes and million, compensation expenses were [ $X.X $XX $X.X and noncash expense. expenses administrative in which research ], noncash were includes stock-based of XXXX stock-based $XX.X General million million million expenses with QX

$XX million $X.XX $XX.X For QX expense million compensation including stock-based was our noncash net XXXX, total. of loss share, in or per

a we of approximately of revised grant our slight from obligations at milestone due For offset guidance related $XX proceeds to our CIRM prior now cash burn increase million the $XXX Servier, of ALLO-XXX expected to program. our million, a by to expect XXXX, impact million our $XX timing

includes impact from expense which full approximately potential expenses excludes guidance million, stock-based $XX compensation million. any business of GAAP to estimated This development $XXX year We activities. noncash expect XXXX operating be approximately

programs. now in Zach, his focus our the comments development to call will I'll over who on milestones key turn core

Jeff. you, Thank

corporate likely new there I'd way second As like LBCL initially I until -- cured recently, line Approximately your relapse. beyond. has the require no patients be treatment our of turn presentation Relations in experience which patients of recurrence second attention the by in R-CHOP or review section Investor development require website. to respond to posted milestones, R-CHOP a will would those X/X versus Unfortunately, disease who to who frontline would to been and know key

potentially the test, after of We practice-changing treatment minimal with patients of LBCL accurate us a watch prediction novel relapses. January, residual disease Because to frontline most could or for and been is believe for of cell has disease an care announced of ability the and to after of for delivered accurate In to we to highly wait likely conclusion This a sema future developing to following standard prognosis decades this test namely identify potential investigational completion partnership disease, frontline give Foresight MRD. treatment those frontline for provide when administered following treatment, a dose frontline relapse. offer who with MRD. relapse to the has the the inability discovery immediately Diagnostics, this potentially relapse, to the action to who a that of and of test are persistent consolidation take after prevent

attributes specific the with cell in of designed is ALPHAX mind. sema

onetime X become be treatment of cell is administered the successful, that First maximizes ALPHAX available it to off-the-shelf frontline allogeneic standard of can seventh cycle cycles eligible R-CHOP. following of discovery with and a cell immediately upon of advantages MRD. If treatment the sema patients could sema foremost, as all MRD

outcomes. understanding with can patients builds T disease on improve CAR ALPHAX therapies administering to growing that low efficacy the Additionally, safety and burden

months, ICANS setting no trial far and Consolidating of outpatient few low the evidence sema immediate after tend to the following of Sema CRS to and already feasible. in many where disease. embedded the patients with R-CHOP R-CHOP, in consolidation to could this begin response Relapses of relapse. permits therapies are cell's an requires making success rates within cell cell Phase pivotal MRD be ALPHAX. test factor autologous MRD a definitive safety speed weeks quickly result frontline an setting The in the use improve in positive critical allow of like following days happen in may in its to within of impending outcome a Sema and further relapsed/refractory prevent post results. action less completion cases, treatment could a I radiological strategy treatment patients profile with to

[ or available As logistics referrals that MRD have waiting penetrating intent T cannot allogeneic cell sema CAR-Ts cell have we for doctors have been the as sema [ in semi have attributes acts will line seen, the reliance of and in or on autologous centers. These ] their cell. CAR won't hindered difficulty to CAR Use [ believe of centers specifics a on adoption cancer treatment cancer like be complex on modality T differentiated reproduce community centers. CAR-Ts rely other be ] use patients. is an autologous there any had We to the ] for earlier the community

like what modalities X. looks You this across on can see journey Slide

sites. Start-up expect well Slide ALPHAX are greater nearing what pivotal regarding and ALPHAX XX are granularity at provides completion several underway activities trial. for to during the

observation of the to visits, scans. include are current fact, sema CT all with or therapy approximately centers. with In of XXX which MRD that sites care, clinic either the randomize positive cancer will patients we selection and the end serial trial of The nearly frontline clinical standard draws is cell have blood consolidation community-based who completed study at

feature of cyclophosphamide without endpoint will and design will primary other and arm survival, event-free fludarabine fludarabine the lymphodepletion ALLO-XXX arms standard used. that differ the With and in plus initially ALLO-XXX. include X the alone cyclophosphamide the treatment regimen One

trial. selection trial of end regimen, the That announced indication the First continue the is will in proceeding we to lymphodepletion is we expected will when mid-XXXX. be the of the of announcement how

milestones The come will next later. a than less study year

diagnosed is safety positive First, at expected patients quickly, expect events quite first analyses enrollment EFS X half the an the efficacy we in follow expect data frontline XXXX. poor, exists, to could the newly interim application the the frontline XXXX. even MRD Knowing or readout in the targeted potentially so and independent the ] And outcome well. biologic monitoring need license trial the data complete is include could lines analysis approved submission the allow This reducing pivotal fee XXXX. effective with half of only come XXXX complex of the agents the ] we to expect for consolidation for X, a will [ more second, of trial of half of decision for to of sema second first to simplifying treatment data board aggregate XXXX we in The need and efficacy study and patients. in cell as of therapy improve rates cure are treatment, of are in for end prognosis who become frontline these the option in readouts because analysis to consolidation perform later in for or of treatment. [ an the this primary If BLA successful, regimens

meaningful The is a clinically XX will I cell create we for advance XX, and derived patients. patients that the treated late-stage Slide could patients rationale with administration and scientific a [ and CLL cells simpler cohort cohort. is onetime There briefly ALPHAX enrolling for the ] these sema next for held [ product strong key ] believe T include On with from now look to dose Phase milestones logistics. AlloCAR an at

modest, would autologous and We enrollment at this response an Considering an expect CAR and of of an complete to move the respectively. dose. into who end initial received T XXXX. we have to went therapy patients those that for all the expect overall on a by the and approved year. fell the Based pivotal complete Phase rate in with I data outcome response who rate the and XX%, XX% rate infusions is response XX% trial complete this The was II response bar readout a trial this trial of recently Phase XX% to of leukapheresis, underwent target in given rate trial,

Importantly, to for have off-the-shelf T are virtually receive infusions. who like CAR all an candidate all sema criteria enrolled cell expected met product patients trial

next-generation attention your our T. is XX in AlloCAR want targeting our program site-specific CDXX autoimmune ALLO-XXX dual integration-based to I CDXX to Slide turn next. wholly owned

for success. Our believe which design centered future on clinical and is scalability development reducing even commercial or both eliminating lymphodepletion, we is rapid absolutely and critical

process analytic We are on manufacturing currently working IND-enabling assay development. and

file We in that expect to first the QX an and of trial begin XXXX. enrolling XXXX IND half in

And concept we unmet trial also so XXXX. result, lupus. We the considering of differentiation indications in have importance proof that with have recognize to other in is concept a of clinical we this end need. we As the of earlier, proof of expect highest are as noted we by recognize

time line TRAVERSE I Phase our for reviews trial ALLO-XXX. XX Slide Lastly,

we potential This treatment-associated response their may needed a data approximately of solid CAR be discovery meaningful now I carcinoma hyperinflammatory function as will quarter, In fundamental that XX, XXXX CDXX-positive we undergoing compromising with is on that planned eradicate mitigate and to plan manuscript update our currently we patients demonstrate renal the Slide The the T year-end A by believe review. the to the algorithm between is have totality, without XX tumors. from detail through and programs. Phase cell flow to what shown XXXX.

now for the to Q&A. open forward additional questions. the you on during our have look any questions pipeline call We answering We'll

Instructions]. [Operator

line of Our Yee the with question first Jefferies. Michael comes from

consolidation progress the of everything. and all yes, on Congrats

question looking on guess to it explain question. I want Phase consolidation. at you breaking it enrolling be patient things. in sites, you'd for think to was study we've question some you're of that how you that X enrollment design know still X-parter speaks to a talked nature a understand sites on as you of numbers? guys I given keep [ I know the the to it's to the be new visibility meaningful are your later are also bullish a would but I the III ] and Can the protocol always the the studies ground. these of trying studies, for

your on that what is the the is to full I And two analysis primary the So between understand of then want EFS that. analysis. confidence part and interim difference

Thanks, Michael. This is Zach. Good questions.

So interest has program market, with in respect relate we that is first oncology sort the the academic as what quite to been question, we from both to will what of share which I'll can centers. as feasibility, community-based this well --

trial academic open a to all enable pace to are have practices of on middle enrollment. sites be those care selected, year and XX been of blend States. We community And of will by expect of sites the That and first in almost have batch United sites clinical to approximately this activate centers. our we tertiary trial

So I trial would been clinical say high. from very these enthusiasm that sites the has very,

second difference around primary Your assessing interim to respectively, in that relates and first the between question half, the events number EFS and interim XXXX, will the analysis. primary half in analyses and at the of the be we

Please for next by stand our question.

Our TB the of question with Van Cowen. next comes Buren from Tyler line

Congrats on all the progress.

trial frankly. the the believe is super likelihood high, I ALPHAX So of succeeding

So being Or after enroll patients why to appreciate positive they this wouldn't the choose undergo do in MRD therapy R-CHOP? of and the risk trial?

Tyler. Thanks,

will They concept signed an malignancy. whether the the -- be that, the attractive has that conversation this think patients of to study them the individual investigators to its do change they're probably case is of assay, for quickly. the potential the that study, not patient potential for come the the about ability their patient be into because way We the there'll trial. this yet. an think and consciousness have see likely practice. the don't -- up for enroll in result I all look So MRD a That's cured believe that made to for respect population general will MRD negative coming highly who to that tell and With we it's to and doctor of

who those for positive. patients Now are MRD

why we've We reasons wouldn't at in the of all really jump also dose a patient a consolidation sema cell receive understand that can't that the for point, to at detailed. chance

be competitive [ potential are of believe time the for of the a enrollment who there therapies during MRD end at are the fairly ] positive. remain this significant launch. frontline, at approved patients We available right us no Importantly, will now emission and but advantage for that

Please next for our stand by question.

Our from Sachs. of next question Salveen comes with Goldman the line Richter

sema the Into cell positive just understand where us what in outcome here as the view data could lies? you and and year-end, clinical bar currently CLL a you help would

Thanks, Salveen.

think is relapsed/refractory bar we fact. population. only So that here as here of CLL matter low in growing the unmet quite is the a this need still And

modest As remarks, we rate. was complete recent mentioned rate during response the product CAR autologous approved and on fairly T a response prepared

Importantly, and infusion we derive believe benefit so to T who fairly that do of quickly the patients an CAR following cells.

the fast of this forwarding now to year. end So

enrolling of we end shared data mentioned, Phase year. this have at we're the we expect now, that cohort As to the I and

Now of course, there will patients. be limited follow-up on those

response However, on we of some to least. have be modest should at patients and some able follow-up rate those

go/no-go next be make we're this us we So year. planning for pivotal that data that expect as helpful will decision for to

for by next stand Please question. our

Our from with of question JMP. the next Reni comes Citizens line Benjamin

by this Are question, that facility right do Or all is that's you especially mainly. you here would out? of to I in feel just the create in in you manufacturing commercialization you States my move be partner? something could this from that ship sema that the guess yourself? feel to is on must with do do related back, the with getting progress, And terms Or really something in have Europe? done a to Europe cell that Congratulations a manufacturing, you forward ready and that, and

Reni, Dave Chang. So this is

me that Let question. answer

market have Union of I to EU, done the We mean are increases bit right are, really significantly. study extremely of cell give ink and deal, I that place the excited something and to in mean, and sema The big previous we this this But drawing. regulatory for chance. gain I also filing asking, potential the the a we to you're European little just rights is how X is now, mean questions our us the is and ready a that signed for experiences prepare we commercialization. clinical U.K.

before us outline Europe. we bit expand give in how to So a plan we little of time

has also can how we an Jeff this is is I believe and the as mentioned, what And best to which program how opportunity we believe a bring Europe. for in can upside expand also partnership, significant much

facility, roughly bay. one. mean manufacturing have Forge own The across X we the that's Cell I second a question, simple our

yes, I the commercial and clinical there think right, facility manufacture that absolutely the designed that's product to clinical the San studies. ship was both beginning Bay. meet well as to you're Europe the requirement and Francisco the U.S. And for as we Europe. can from for regulatory And

question. Please stand by for next our

question next Luca line of from the comes Our Issi Capital. RBC with

On the progress, just in a one for about maybe Can you, talk you the powering ALPHAX. Zach. quick assumption

the expected I thinking prior like for never in months in I as that corporate anything your you read ] for into arm the that that are the the how EFS actually product control actually to new you but given longer arm, And media your see active think also [ deck, that? tested about EFS X median no deck setting.

appreciate So there, must it. any color I

Thanks, Luca.

that gone for powering haven't into overall the we assumptions details we So made study design. the around

you'll the versus to As consistent patients size remained sample XXX note, has XXX.

R-CHOP. with X somewhere context in And fair which X for so that's X unfold actually, public initiation months that will a was from we literature As events of far EFS the featured the study. previously of the patients the And as between the on of it's probably arm, amount control had of to based on really actually timing the counting R-CHOP. months, treated

second question? The

treatment. expect we -- control under What

Yes.

publicly. for powering to what the So or as back this far is treatment we're again, going to guided the as to so haven't what arm, we control which get assumptions, anticipating we

the patients CR. However, experience who in achieved suggests we that well is to can stay that number CR, what tend to very from and program a they say tend have That's do I do one. point the we Phase that

cells to two, treatment relative And point literature the with lead CAR refer body to of number T better efficacy at burdens disease to growing again does tend I'll outcomes. low suggest that to

experience this work have MRD So that population, well, don't to we'll will suggest the hands-on a able over evidence patient actually the to while control in improve significantly quite quite bit we there's and a be positive arm. of EFS

And how look, as this me at event for ] saying is big a PFS. YESCARTA as treatment well led see just second-line the on essentially let the size, the add setting just in study that [ practice. of by I study changed the and successful would EFS And well the was look powered a to sample and that bringing ask you Brian to that atom forward

Please for stand next by our question.

line from of with comes question Asthika Truist. next Our the

I'll well sema this confidence ask, enthusiasm they've arm, control cell arm also on under I [ financing ]? question. given going to they on that have to also of Alpha Servier to a what's congratulations to compel under control that rights know the shared you're and my And from just [ on I'm in -- ] offer the But that as stay the going to when going saving patient for Tyler's been they're active the going the off spin in I'm X. announced.

is really what's persistence now of squeeze much terms another can if is important. know LBCL how CLL We What then I CLL, right one in. do In you in we needed? upfront needed. killing how about quick is persistence know much And tumor with

Thanks, Asthika.

who So to control the get back on to arm. question the patients the randomized

they're couple least closely in into in and them control trial, closer the very so I getting higher clinical reasons closely because follow-up. context the at going So to Probably they there's would trial. standard is even a context often Putting of for clinic they the the [ focus as arm. hat that as of would forth reassuring think of clinical followed to it's my be stay so on, and quite patients on on be much the ] followed care a for a that know being of patient

if going I patient knowing hawk, patients. to care, a watched go I'm getting reassuring the way long a So of I'm that like standard will a think be I'm to but

a even is for reiterate if for I'll a therapies decide approved discontinue that going patients then to remission in disease. LBCL There find are patients who going those can it's their though They're on for relapse. they MRD no as to the clinical who And not have physician trial, currently. to treat are to still them with wait

With quite to of around context be the for We do cells second number been stay for question of a beyond. think we period hole. our in developing a into still in the persistence, I cases, able show have can to and around that too cells rabbit time. that on months, And LBCL evidence of that some X to months CLL And is dive there. have I not we the of think sort deep around these need know

create -- with our in cells these window there So current get for regimen, and of a lymphodepletion do eradicate tumor. we persistence FCA-based we nice to

of Since the significant studied I have and we study, study comment, study, will And KOLs, at behave not the the the how the input the design as designed both well well design that yes, which would but well community-based randomized in the they about was arm. as the on to make. control a their as the as enrolled about let opinion with from unanimous will academic-based handle KOLs, and patients KOLs how are mean study. point, the this study I add one just me like how to once enroll this questions

terms the are have a the comfort making enthusiasm lot I about they support think we the conduct in of lot, study, we will So that of that have investigators projections how enrollment cadence. are expressed, the the a that's given of which relying study we level where about

you. Thank

from line with Our Cheng Brian next question comes of the JPMorgan.

is an is there lymphodepletion. essentially bring that reality? factors tell us CAR the likelihood of a autoimmune, optimizing some that completely you of expansion. your the Can of key perspective on On to whether lymphodepletion question T eliminating What are

we for that hoping the initial question. take me XXXX, get autoimmune, let IND Brian, the planned advancing of have program by is said, that we of communicated we ] concept are Again, quarter first Yes, to as year-end. and [ are the the on in the ALLO-XXX proof

of from renal or allogeneic cell have that CDXX is the lymphodepletion ALLO-XXX, as needed not. something have well whether looking a the T which thought we is This with question our carefully, ALLO-XXXA, T of program the CAR program, is is as carcinoma. patients CDXX The where through at we that have very number treated CAR we this data

have very the together is that CAR and know data T much Dagger cells And on capability behaves allogeneic cells. looking how very remarkably all terms the of So CAR T clear combining in technology, the those when we expansion T seen CAR at well. depends we of translational you the that data expand have

that's information, one. number So

Number that We what reset XA reset is that's depletion, is of with And the ] put immune have T the believe ALLO-XXX that deep two, theme in autoimmune the required. to as initial believes necessary disorders. the the persistence we this patients do many and KOLs view nobody system is we information will common that, of depth of believe is with not, information well, and system. also, B-cells will well. the is the to [ immune all we when depletion, we and we important. we believe depletion is together, critical But cells, expand One achieve

Please stand by question. for our next

Blair. comes line the Sami next from of Corwin with question Our William

in decided just ] just seem look negativity remission. long-term could the not the of kind to does endpoint as being predictive then And curious after lymphodepletion [ considering a enrolled ALPHAX versus trial? clarify secondary selection. you the wondering in I patients of to if that a you at it X will be how be in many of why MRD analysis interim arms initially enrolled was I XXX

Thanks, Sami. questions. Great

really gone we patients detail are around be to many how that haven't enrolled into X-way in So going randomization.

have have we XXX take told hypothesis on However, place treatment said arm. the in of arm control sort that arm approximately on versus each will patients

enroll. safety the patients and relative a that selected give overall how on fraction number of was additional that And on enrollment. translational a forward ] receive may you bit informed carried go duration efficacy the well would of [ So number to to blend is outcomes. an of large of through a an not that patients decision enrollment. yet and to regimen give idea it's who we the make right statistical to can a But LDH many then not of us the little power It's enroll -- of need

MRD, As the on endpoint for question exploratory far as clearance secondary this examining as an be we endpoint. will MRD

lot make for very place. in to that probably same a the However, sense as using first to patients key of secondary test we select enrollment given do a endpoint, were the didn't the it

to II for a endpoints -- future as We Phase excited in we but [ this to by Phase for ] endpoint are clinical potential thought key it like trial. stick the MRD trials, best clearance III quite the traditional EFS

from next question Baird. comes Jack with Our the of line Allen

in could ALLO-XXXA, material you acquisition X. And should really the on Cell reacquisition CLL ALPHAX study Cell say, ask or the the so running I to you for patients? in your planning of our X Or global Forge for about wanted rights then and to view? we are for committed and Are look producing that Forge a from out as the ALPHAX U.S. X become the ALPHAX on global or

great and clinical fully and and Jack, questions. the optional is remind we second Jack, to don't that do question? in supply, terms are And something details. into of Cell mean with the I study. materials go you this can the that's question, that second for what X, is that facility, GMP just necessary conduct us us the we both it's our ALPHAX The GMP producing Forge CLL

Yes. I about the reacquisition rates asking the [indiscernible]. was of

Yes.

in -- Servier have in we are that, about expanding these trial very clinical we extended commercializing that of So with obtained U.K. the rights the to in prepare And from footprint Europe we as yes, interested is and obviously, terms rights territories.

So that, I as signed on a just said, deal. we

So we information those I doing what in more provide time. would future ask to territories stay are tuned. We'll you on in

next Canaccord. of question comes from line Our Newman the with John

ALLO-XXX autoimmune I'd in progress the like setting. question had about as my add well. to all congrats on the a I

competitors growing is [ your studies. an considering is, but including running of be and your there filing My Some an dermatomyositis actually they're separate orphan given patients there, autoimmune in more strategy ] that they're are are including or patients you the might study it interesting studies disease? question area, in

Thanks, John.

the submission. details the think development clinical on ask stay IND bit I get I'll we little as for closer to tuned a to further plan you of kind

prepared for to also proof out existing at As looking the we in looking mentioned there the the we're going concept development differentiation in be remarks, but carefully of opportunities for plan.

So please stay tuned.

concept, interest. in component of That initial only has cell expand not And indications the once obtain a proof where exciting ALLO-XXX play space. we the into on. There of can indications this where program. CAR many proof also a the lot autoimmune is program And T mean different I very a but proven, also John, bigger indications let me is that add just role. concept, of is a T may includes

As component key role we to the CDXX biology ALLO-XXX that the and the one talked activated has important just differentiation innovation pretty having of the dagger also in is ability which a we CDXX the bring believe we a a CDXX address introduced reminder, into pathogenesis have dual as autoimmunity. about, the but cells, has and T

next B. of the Patel from Kalpit comes question with Our Riley. line

This an planning auto have or get you B-cell ALLO-XXX to to earlier initially you'll that reduce of Ts related diseases but with is lymphodepletion. multiple dose seen depletion doses do profound need you're the since in we to question, use the of of autoimmune CAR sort that think

Let me take question. the

to we are of maximize ALLO-XXX. to the rely We on -- benefit are infusion not planning single

of the from line Samantha comes question next with Citi. Our

onset that are diagnostic treatment might think algorithm characterize ALLO-XXX, study? autoimmune potential as you you the how you how TRAVERSE you the [ well? the applicable ]. in effect bit With of associated on you've the dual Just hyperinflammatory targeting by just observed thinking response the can have about approach, that treatment you the population is that developed, used be hematologists that to a And and given

great Samantha, Yes, question.

Let that me take question.

leverage the expansion And follows. cell great we T, are with that pharmacodynamic to there of ALLO-XXX effect any generated a expansion, we the remarkable reviewed program, which CAR when ALLO-XXX, seen have where there's That's the we extensively after think about pretty really not the that infusion. have like How we cell scalability is data intend have autoimmune critical. go we large those on We the when to we as a therapy cell is way this the address questions, high cell one And is see of very do indication. the we space, heavily. is it And up it view is to dose. hyper-inflammatory response is

is autoimmune can that space. meet from the number where demand this So the patients ALLO-XXX a manufacturing perspective of the provide of can and situation others

will come anything, with leveraged the programs autoimmune ALLO-XXX the increase if that capability we capacity may be ALLO-XXX. expansion the which to So can expand with with

you. next Please by question. our stand Thank for

Our with Guggenheim. next question comes Kelsey from the of Goodwin line

progress. the all on Congrats

you just XXX, end advance guess, in remind the and benchmark in maybe you'd to order further? For the at could this what need see efficacy of RCC the us program I year to

Thanks, Kelsey.

are the still been There's So approval a poor. relapsed/refractory RCC there. quite outcomes recent

in However, rate it response much terms approved didn't make over really agents or existing third-line of headway response here. durability

low. So is we that, that bar think still quite

were back we tumors as Some response at were rate recall, whose above when to XX% express of you looking XX% CDXX. that known benchmark AACR with the patients from we response the data in at around And that rate year, a shared what somewhere last we're literature. the is

encouraged pretty by of So sign that early we're efficacy.

our for next by stand question. Please

Prendergast from Our next Raymond Laura James. comes with question of line the

me. for One

center, your you readiness anticipate cell testing and for what for center Just versus community might at sema barriers you thinking MRD see about barriers there? any the the academic

extremely other this now well docs well. giving as indication, these ], centers of approaching saying several T been question. finding bispecifics to that to I'll actually, course, experience that this those that's for these what is trial. Laura, equipped run community CAR these we're without hands-on by months have are bispecifics patients for for to And because even centers indications [ Thanks, start we're the for that corner

T the us the across so adverse handle they'll that enough able different profiles and the has be unique trial. are confidence share given therapies and on events this ] [ that cell-directed think And toxicity patients treated I both modalities, that to the

is these decade, not shelf, in centers barriers that from off the barrier operational think they there of logistical cell is into that jumping as been another CAR shipped of at to many the I in course, and be last on and T administered lot that the is have Of sema outpatient. category a can kept undertake an band, it's just their and Because centers. willing has cases,

barriers logistical go that of face All those away. and these operational centers

experience. even found fact, actually is an And quite in partners, we don't direct on T set of what have those open so hands in have who and enthusiastic CAR

from Stifel. Burnett line of Ben comes question the next with Our

Good Carolina Ben Burnett. afternoon. This is Ibanez-Ventoso for

with and to do the it cell. will fair second for clinical ALPHAX the as be given sema ALLO-XXX ALLO-XXX MRD First, trial separately, the look would administration you. a window after a trial, assessment the at initial Dagger on then before lymphodepletion, the later this in but the of update from safety And TRAVERSE based year you the Thank ALLO-XXX? expected technology,

Carolina. Thanks,

to days time. tumor that be there be the short are be window X is clinical in that tend the we timing the will specifics MRD around of that generally assessments trial. first not question, tend not So I to performing because to test likely of and does the into it of in that such the a the speaking, say going turn we'll dynamics avoid in still matter that will of negative the cleared

assessment such an would questionable. of utility the So be

were will and the propel whether biology question very and the potential that an share say or we strongly Dagger we The asked efficacy cells at of as for in persistence. we the around outcomes believe you biology XXX to engraftment was good carefully to in AID second specifically population TRAVERSE ability these to designing a the this and trial looked that later very window efficacy the ALLO-XXX year we that offer TRAVERSE update from I'll

further much go that. wouldn't than I

think I AID are single This oncology. in targeting CAR. CAR persistence different requirements is cell dual the a for versus versus a targeting

think in results there design differences construct -- think to us all for I is that it's sufficient population that going I instructive to read all it's and that don't XXX the into that scrutinize So XXX. and be

any further Ladies and over queue. questions like the I'm now gentlemen, no you. Thank turn showing comments. back to call additional I to in the management would for

operator. you, Thank Yes.

remain sure are competitive of and future. all fronts and on to Allogene we making in We how strengthen continue today proud the very we

continue resources we positioned well positioned importantly, data advancing runway on we we into to core financing, landscape And program. patients. extend all treatment well to more the our of today's cash important CAR benefit the believe change And to are We focus with will the announced for readout. are our T

for thanks today call joining investors to gratitude you Operator, now on our us to sincerest may our disconnect. Our and the your support. continued you for

for Ladies that and participation. gentlemen, today's your you call. Thank conference concludes

You may now disconnect.